An Investigational New Drug (IND) application for KF1601, a chronic myeloid leukemia (CML) treatment was submitted to and approved by the Korea Ministry of Food and Drug Safety by ImmunoForge, the manufacturer of the drug.
KF1601 is a novel synthetic oral tyrosine kinase inhibitor-targeted therapy that inhibits the fusion gene BCR::ABL1. KF1601 effectively inhibits the T315I mutation during the nonclinical development process and is safe and tolerable, the company wrote in a press release.
